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The silent mating type information regulation 2 proteins (sirtuins) 1 of class III histone
deacetylases (HDACs) have been associated with health span and longevity. SIRT1, the
best studied member of the mammalian sirtuins, has a myriad of roles in multiple tissues
and organs. However, a significant part of SIRT1’s role that impinges on aging and lifespan
may lie in its activities in the central nervous system (CNS) neurons. Systemically, SIRT1
influences energy metabolism and circadian rhythm through its activity in the hypothalamic
nuclei. From a cell biological perspective, SIRT1 is a crucial component of multiple
interconnected regulatory networks that modulate dendritic and axonal growth, as well as
survival against stress. This neuronal cell autonomous activity of SIRT1 is also important
for neuronal plasticity, cognitive functions, as well as protection against aging-associated
neuronal degeneration and cognitive decline. We discuss recent findings that have shed
light on the various activities of SIRT1 in the brain, which collectively impinge on aging-
associated disorders and lifespan.
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INTRODUCTION
The sirtuin family comprises of class III protein deacetylases,
which unlike the class I and II histone deacetylases (HDACs), have
an obligatory dependency on nicotinamide adenine dinucleotide
(NAD) as a cofactor (Blander and Guarente, 2004). Sirtuins
deacetylate a wide range of histone and non-histone targets, and
influence multiple aspects of cellular and organismal physiology
and pathology (Haigis and Sinclair, 2010; Sebastián et al., 2012;
Chang and Guarente, 2014; Herskovits and Guarente, 2014).
The most prominent of the latter is health and lifespan, and
the notion of sirtuin activities being systemically beneficial
to multiple organs, particularly in the later years of life, has
attracted tremendous interest in recent years (Tang, 2011).
The family’s founding member, Sir2 of S. cerevisiae, mediates
transcriptional silencing of the yeast mating loci, telomeres
and the ribosomal DNA (Imai et al., 2000). Its suppression
of the formation of rDNA circles (Sinclair and Guarente,
1997) could play a role in extending yeast’s replicative, but
not chronological lifespan (Kaeberlein et al., 1999; Fabrizio
et al., 2005). Importantly, yeast Sir2’s lifespan prolonging activity
is also proposed to be biochemically link to, and with its
activation mimicking, the effect of caloric restriction/dietary
restriction (CR/DR) (Lin et al., 2000; Anderson et al., 2003;
Cohen et al., 2004). CR/DR, a regime of moderate reduction
of food intake without causing malnutrition, was known to
curb metabolic disease as well as extend lifespan in many
animal models (Chung et al., 2013). The notion that CR/DR
acts through sirtuin has been intensely investigated and debated
(Kaeberlein and Powers, 2007; Cantó and Auwerx, 2009a,b;
Guarente, 2013; Park et al., 2013). This putative mechanistic link
is one reason for the heightened interest in sirtuins as potential
drug targets for pharmacological intervention of metabolic
disorders and aging (Baur et al., 2012; Chakraborty and Doss,
2013).
Over-expression or activation of Sir2 orthologues was also
shown to increase lifespan of invertebrate models such as C.
elegans and Drosophila (Tissenbaum and Guarente, 2001; Rogina
and Helfand, 2004; Wood et al., 2004). These results have been
challenged by more recent works that suggest that the lifespan
extension effect was smaller than previously reported (Burnett
et al., 2011; Lombard et al., 2011; Viswanathan and Guarente,
2011). The mammalian genome has seven sirtuin paralogues
(Michan and Sinclair, 2007) that are differentially localized to
the nucleus, cytoplasm and mitochondria. Whether sirtuins are
bona fide longevity factors in mammals and humans has been
unclear (Naiman and Cohen, 2012; Park et al., 2013). Sirt1, the
mammalian paralogue sharing the highest homology to yeast
Sir2 and the best studied, could be either pro- or anti-survival
(for example, cancer promoting) under different contexts. Unlike
the case in yeast, earlier experiments with transgenic over-
expression or pharmacological activation of SIRT1 in mice
improved metabolic parameters later in life (Baur et al., 2006;
Alcendor et al., 2007; Milne et al., 2007; Herranz et al., 2010),
but did not significantly increase lifespan in mice (Herranz et al.,
2010). However, several recent reports have collectively provided
strong evidence that sirtuins could indeed prolong the lifespan
of mice. Transgenic over-expression of SIRT6 was shown to
increase the lifespan of male (but not female) mice, likely through
its influence on Insulin-like growth factor 1 (IGF-1) signaling
(Kanfi et al., 2012). Recently, SIRT2 was found to increase
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lifespan of mice hypomorphic for the mitotic checkpoint kinase
BubR1, the level of which declines in aging and aging-associated
diseases (North et al., 2014). Importantly, mice with brain-specific
transgenic over-expression of SIRT1 (BRASTO) have also recently
been shown to have an extended lifespan (Satoh et al., 2013),
and the specific SIRT1 activator SRT1720 extends lifespan of
mice even when these were fed a standard diet (Mitchell et al.,
2014).
The aging-delayed and lifespan extension phenotype of
brain-specific Sirt1-overexpressing mice (Satoh et al., 2013) is
particularly interesting, and attested to the notion that SIRT1
may effectively influence aging through its activities in the
central nervous system (CNS) neurons. SIRT1’s deacetylation of
transcription factors such as the forkhead box class O (FoxO)
family members (Brunet et al., 2004; Huang and Tindall, 2007),
TP53 (Hasegawa and Yoshikawa, 2008) and nuclear factor κB
(NF-κB) (Yeung et al., 2004; Chen et al., 2005) modulates key
aspects of stress response and survival pathways in postmitotic
neurons. In C. elegans, the FoxO orthologue Daf-16 (Ogg et al.,
1997) mediates lifespan extension downstream of the IGF-1
receptor/Daf-2 (Kimura et al., 1997) mutant in worms, and
restoring Daf-2 expression in worm neurons alone negated
the lifespan extension effect of Daf-2 mutants (Wolkow et al.,
2000). This suggest that IGF-1 receptor/Daf-2 signaling in
neurons could be critical for lifespan and that this could be
influenced by sirtuins through FoxOs. As the enzymatic activity
of SIRT1 is regulated by NAD+, it is therefore a key nutrient
and redox sensor in the energy expensive brain. SIRT1’s role
in regulating the activities of key transcription factors (e.g.,
peroxisome proliferator-activated receptor gamma (PPAR-γ) and
its transcriptional co-activator PPARγ coactivator-1α (PGC-1α)
and transducer of regulated CREB2 activity 2 (TORC2)) and
enzymes (e.g., phosphoglycerate mutase-1) in energy metabolism
in peripheral tissues are well known (Cantó and Auwerx, 2009b;
Sugden et al., 2010; Li, 2013; Chang and Guarente, 2014).
However, metabolic control in mammals is centrally exerted
through sensing of energy status in the hypothalamic neurons
in the brain, and SIRT1 activities in these neurons influence the
development of aging-associated metabolic disorders (Chang and
Guarente, 2014; Toorie and Nillni, 2014). SIRT1’s neuroprotective
functions are also well known (Tang, 2009; Zhang et al., 2011b).
However, by regulating neurite growth and synaptic processes,
SIRT1 was recently shown to also play a role in normal
cognitive function and synaptic plasticity (Gao et al., 2010;
Michán et al., 2010), which is beyond its better known role in
countering cognitive decline and neurodegenerative disease in
aging.
In the ensuing paragraphs, we highlight recent findings that
elucidated the functions of SIRT1 in the brain, and discuss
how disruptions of these functions may underlie aging-associated
disorders and lifespan.
SIRT1 IN CNS NEURONS—ROLE IN NEUROGENESIS,
NEURITE GROWTH NEURONAL NETWORK CONNECTIONS
SIRT1 is ubiquitously expressed, but more targeted investigations
have revealed high levels of expression in the developing mouse
CNS (Sakamoto et al., 2004; Ogawa et al., 2011), adult mouse
and human brain (Ramadori et al., 2008; Zakhary et al.,
2010) as well as the porcine brain (Shan et al., 2009). Within
the adult brain, SIRT1 expression is found in most brain
regions, is prominent in neurons of the hippocampus and
hypothalamus (Ramadori et al., 2008; Michán et al., 2010;
Zakhary et al., 2010), and is mostly nuclear. Brain SIRT1
levels are decreased in aged neurons (Quintas et al., 2012),
and are downregulated by a high fat diet (Wu et al., 2006;
Heyward et al., 2012) and various neuropathological conditions
(Pallàs et al., 2008; Julien et al., 2009). On the other hand,
SIRT1 levels in brain neurons could be increased by CR/DR
(Satoh et al., 2010; Quintas et al., 2012) and physical exercise
(Falone et al., 2012; Revilla et al., 2014). SIRT1’s high levels
in the mammalian CNS and the way these change with
physiological and pathological stimuli are indicative of functional
importance.
SIRT1 activity is known to affect fate determination of neural
progenitor cells (NPCs) during development. SIRT1 activity
is dependent on the redox state, and under conditions of
oxidative stress, SIRT1 promotes differentiation of NPCs towards
the astroglia lineage partly by limiting the levels and activity
of the pro-neuronal transcription factor Mash-1 (Prozorovski
et al., 2008). Differentiating neural cells from 8-oxoguanine DNA
glycosylase knock-out mice spontaneously accumulate mtDNA
damage and concomitantly shift their differentiation direction
toward an astrocytic lineage, a result of an increased NAD/NADH
ratio and SIRT1 activation (Wang et al., 2011). SIRT1 inhibition
or silencing was shown by several authors to promote neuronal
differentiation (Prozorovski et al., 2008; Zhang et al., 2011a; Liu
et al., 2014) and increased neuronal production in both the
subventricular zone and the hippocampus (Saharan et al., 2013).
Sensory neuron differentiation from progenitors is dependent
on SIRT1’s modulation of the acetylation status of Pax3, which
acts upstream of Hes1 and Neurog2. SIRT1 silencing increased
the level of acetylated Pax3, with consequential decrease in
Hes1 (important for stem cell maintenance) and increase in
Neurog2 (important for neuronal properties) activities, thus
promoting neurogenesis (Ichi et al., 2011). In a different
context, however, pro-neurogenic Bcl6 was shown to promote
neurogenesis through SIRT1 recruitment, with the silencing of
Hes-5 downstream of Notch signaling (Tiberi et al., 2012).
Another report has indicated that SIRT1 inactivation in the adult
brain resulted in the expansion of oligodendrocyte progenitors
that could generate myelinating oligodendrocytes (Rafalski et al.,
2013).
Other than neural cell fate, manipulations of SIRT1 levels and
activity have also been shown to modulate neuritogenesis—the
outgrowth of axons and dendrites. Cytoplasmic SIRT1 enhanced
nerve growth factor-induced neuritogenesis in PC12 cells (Sugino
et al., 2010). Insulin-induced neurite outgrowth of SH-SY5Y cells
is dependent on SIRT1 (Liu et al., 2013b). Primary neurons from
transgenic mice overexpressing SIRT1 have enhanced neurite
outgrowth and survival apparently via negative regulation of
mammalian/mechanistic target of rapamyscin (mTOR) signaling
(Guo et al., 2011). SIRT1 has been detected at the axonal growth
cone and its activation has a positive influence on both formation
and elongation of axons, likely through deacetylation of AKT
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FIGURE 1 | Roles of SIRT1 in neurogenesis and gliogenesis. (A) In
neural progenitor cells (NPCs), repression of Notch-dependent Hes5 genes
by Bcl6 is important for neurogenesis. Bcl6 triggers exclusion of
co-activator Mastermind-like 1 and recruits SIRT1 to inhibit transcription of
Hes5, promoting neurogenesis. (B) Pax3 acetylation on C-terminal lysine
residues K437 and K475 is critical for regulation of Hes1 and Neurog2.
SIRT1 silencing increased acetylation level of Pax3 and subsequently
decreased the promoter activity of Hes1 but increased activity of Neurog2,
inducing sensory neuron differentiation. (C) Under oxidative condition in
NPCs, SIRT1 is upregulated and binds to transcription factor Hes1. This
subsequently inhibits pro-neuronal Mash1 and leads to astrogliosis.
(Li et al., 2013). Regeneration of peripheral axon after injury is
SIRT1-dependent, and SIRT1 targets miR-138, a suppressor of
the axonal regeneration process which could in turn reciprocally
suppress SIRT1 expression (Liu et al., 2013a). Overexpression
of SIRT1 in hippocampal neurons enhanced dendritic arbor
complexity, an effect that is mimicked by its activator resveratrol
(Codocedo et al., 2012). Brains of Sirt1 knockout mice was also
shown to exhibit a decrease in dendritic branching, branch length,
and complexity of neuronal dendritic arbors (Michán et al.,
2010).
Taken together, these results suggest that SIRT1 could
influence neuritogenesis of both axon and dendrite via several
targets and mechanisms (Figure 1). This would also mean that
SIRT1 is likely to have a role, like those documented for the Class
I and II HDACs (Gräff and Tsai, 2013), in the connection and
plasticity of the neuronal network.
SIRT1’S ROLE IN SYNAPTIC PLASTICITY AND COGNITION
SIRT1 has a widely recognized role in neuroprotection and is
antagonistic against progression of neurodegenerative processes
(Tang, 2009; Srivastava and Haigis, 2011). Its role in synaptic
plasticity and cognitive function was therefore more often
associated with a reversal of neuropathological conditions that
impairs learning and memory. Whether SIRT1 has a role in the
physiologically unperturbed versions of learning and memory
was clarified only recently. Sirt1 knockout mice have grossly
normal brain anatomy, but exhibited a dendritic development
phenotype as noted above (Michán et al., 2010). These mice
exhibited defects in synaptic plasticity, although parameters
such as basal synaptic transmission are indistinguishable
from wild type. Behavioral tests indicated that short-term
memory, long term associative memory, as well as spatial
learning are all impaired in Sirt1 knock-outs compared to
control. The knock-out mice’s hippocampal Schaffer collateral
pathway also exhibited a defect in long term potentiation
(LTP).
A conditional knockout of SIRT1 in brain (loxP-flanked
exon 4 of Sirt1 with Cre recombinase driven by the Nestin
promoter) also resulted in a decrease in fear-conditioning and
other short-term memory, as well as hippocampal CA1 LTP (Gao
et al., 2010). SIRT1-deficient brain had grossly normal anatomy
and CA1 neurons had normal basal synaptic transmission.
However, the SIRT1-deficient hippocampus had decreased levels
of synaptophysin, a marker of the presynaptic termini, and CA1
neurons in these have decreased dendritic spine density. Analysis
of known genetic and epigenetic modulators of learning and
memory in SIRT1-deficient brain revealed that the levels of a
key neurotrophin regulating neural development and synaptic
function, the brain-derived neurotrophic factor (BDNF), is
reduced. This is explained by a reduction or abolishment of
cAMP response element-binding protein (CREB) binding to
several BDNF promoters, as the levels of CREB protein (but
not mRNA) is downregulated (Figure 2A). The reason why
CREB levels are reduced in SIRT1-deficient brain was traced
to an upregulation of the levels of miR-134 (which SIRT1
suppresses reciprocally). miR-134 is brain-enriched, and one of
its known role is the regulation of dendritic spine size and
morphology through modulating the expression of Lim-domain-
containing protein kinase 1 (Limk1) (Figure 2B). SIRT1 limits
the expression of miR-134 as part of a YYI-containing repressor
complex, and promotes BDNF transcription. However, BDNF
production may affect mTOR signaling pathway activation,
which will also suppress miR-134 activity. The latter also
has an effect of relieving miR-134’s repression of Limk1
translation, which promotes dendritic development (Schratt et al.,
2006).
SIRT1 could also modulate BDNF expression via the
deacetylation of methyl-CpG binding protein 2 (MeCP2; Zocchi
and Sassone-Corsi, 2012), a transcription factor mutated in the
neurodevelopmental disorder Rett Syndrome (Guy et al., 2011;
Liyanage and Rastegar, 2014). BDNF transcription could be
elevated by this MeCP2 deacetylation, which promoted its release
from the BDNF promoter (Guy et al., 2011; Figure 2C). The
presence of high levels of SIRT1, particularly in the hippocampal
neurons, may therefore serve a role (amongst others) in synaptic
plasticity through the modulation of changes in dendritic spine
functions and connections.
From the above discussion, it is easily conceivable that
reduction of SIRT1 levels in the aged hippocampus could result
in short term memory deficits and cognitive impairment. Aging
human adults often exhibit more delocalized brain activity
connected to higher order cognitive functions, and recruitment
of additional brain areas was proposed as a compensatory
mechanism for age-dependent functional decline in the primary
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FIGURE 2 | The Role of SIRT1 in synaptic plasticity. SIRT1 modulates
synaptic plasticity through the regulation of BDNF. The SIRT1 and YY1
complex limits the expression of miR-134 which affects the CREB-BDNF axis
(A) and leading to enhanced Limk1 protein synthesis (B). The release of
BDNF activates mTOR signaling pathway which suppress miR-134 activity.
MeCP2 deacetylation by SIRT1 could also promote BDNF transcription (C).
areas (Cabeza et al., 2002; Bishop et al., 2010). Aging-associated
decline in SIRT1 levels may also impair the plasticity of more
distant connections. SIRT1 also has other functions in brain
neurons that would contribute to aging and its associated
disorders, as further discussed below.
SIRT1 IN HYPOTHALAMIC NEURONS—CONTROL OF ENERGY
METABOLISM, CIRCADIAN RHYTHM (AND LIFESPAN)
The hypothalamus regulates important aspects of metabolism
through its neuroendocrine control of the pituitary gland
hormones, and regulates body temperature, hunger/satiety
and circadian rhythms, amongst others. Major neurons
regulating hunger and food intake in the arcuate nucleus of
the hypothalamus are the anorexigenic pro-opiomelanocortin
(POMC)-expressing neurons and the orexigenic agouti-related
peptide (AgRP) expressing neurons (Morton et al., 2006), and
recent findings indicate that SIRT1 has major roles in metabolic
homeostasis via its activity in these neurons (Table 1). Inhibition
or silencing of hypothalamic SIRT1 in rat (by intracerebro-
ventricular administration of inhibitor and siRNA) decreased
food intake and body wright via a FoxO1-mediated increase in
POMC and decrease in AgRP (Cakir et al., 2009). In rats with
diet-induce obesity, brain SIRT1 inhibition increased POMC that
leads to an increase in α-melanocyte-stimulating hormone (α-
MSH), which could in turn increase thyroid releasing hormone
and T3 levels (Cyr et al., 2014).
Hypothalamic SIRT1 protein levels increase on feeding, and
SIRT1 suppresses the expression of orexigenic AgRP (Morton
et al., 2006; Sasaki et al., 2010). Conditional knock-out of SIRT1 in
AgRP neurons (loxP-flanked exon 4 of Sirt1 with Cre recombinase
driven by the Agrp promoter) decreased their responses to the
hunger inducing hormone ghrelin (Dietrich et al., 2010). Imai
and colleagues’ BRASTO mice with transgenic over-expression
of SIRT1 in the brain (mouse Sirt1 driven by mouse prion
(PrP) promoter) had conversely an enhanced response to ghrelin
(Satoh et al., 2010). On the other hand, conditional knockout
of SIRT1 in POMC neurons (loxP-flanked exon 4 of Sirt1 with
Cre recombinase driven by the Pomc promoter) was shown to
reduce energy expenditure and increase susceptibility to diet-
induced obesity, as well as signaling processes induced by the
satiety hormone leptin (Ramadori et al., 2010). In a recent
report in which SIRT1 was conditionally overexpressed in mouse
POMC or AgRP neurons (using Rosa26 locus knockin and
induction by Pomc- or Agrp-Cre), the authors observed that
over-expressed SIRT1 prevented age-associated weight gain in
complementary ways (Sasaki et al., 2014). Over-expression of
SIRT1 in POMC neurons stimulated energy expenditure, whereas
overexpression in AgRP neurons suppressed food intake. Mice
with brain-specific SIRT1 knock-out (BSKO: loxP-flanked exon 4
of Sirt1 with Cre recombinase driven by the nestin promoter) have
defective somatrophic (growth hormone and IGF-1) signaling
(which could be due to Sirt1’s recently documented inhibition of
CREB Monteserin-Garcia et al., 2013), as well as CR/DR response
(Cohen et al., 2009).
SIRT1’s regulation of energy (glucose and lipid) metabolism
in peripheral tissues are well known (Chalkiadaki and Guarente,
2012; Li, 2013), and SIRT1 has been associated with induction
of hepatic gluconeogenesis (Rodgers et al., 2005), pancreatic
insulin secretion (Bordone et al., 2006), enhanced muscle
insulin sensitivity (Schenk et al., 2011) and the “browning” of
white adipose tissues (Qiang et al., 2012). The SIRT1 activator
resveratrol when acutely administered into the mediobasal
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Table 1 | Summary of SIRT1’s roles in metabolic homeostasis.
No Model Manipulation Observation Reference
of SIRT1
1 POMC expressing neurons Knockout Increased α-MSH, increased
thyroid hormone and T3 levels,
reduced energy expenditure; hence
more sensitive to diet-induced
obesity
Ramadori et al. (2010, 2011),
Cyr et al. (2014)
2 AgRP expressing neurons Knockout Decreased response to hunger-
inducing hormone ghrelin, reduced
food intake
Dietrich et al. (2010)
3 Peripheral tissue neurons Knockout Increased insulin sensitivity and
insulin receptor
Lu et al. (2013)
4 BSKO mice Knockout Defective somatrophic signaling
(growth hormone and IGF-1)
Defective caloric restriction
response
Cohen et al. (2009);
Monteserin-Garcia et al.
(2013)
5 AgRP expressing neurons Over-expression Reduced food intake Sasaki et al. (2014)
6 POMC expressing neurons Over-expression Stimulated energy expenditure Sasaki et al. (2014)
7 SF-1 expressing neurons Over-expression Increased resistance to diet-
induced obesity and reduced
susceptibility to insulin resistance
Ramadori et al. (2011)
8 Mediobasal hypothalamus Activated (by resveratrol) Improved insulin sensitivity Knight et al. (2011)
9 Mouse forebrain Over-expression Obesity, impaired glucose
tolerance, some defects in motor
functions
Wu et al. (2011)
10 BRASTO mice Over-expression Enhanced response to ghrelin
hormone
Satoh et al. (2010)
hypothalamus (containing the arcuate nucleus) improves insulin
sensitivity, and this is negated by SIRT1 inhibition or silencing
(Knight et al., 2011). Conditional deletion of SIRT1 in mice
in steroidogenic factor 1 (SF1)-expressing neurons (loxP-flanked
exon 4 of Sirt1 with Cre recombinase driven by the Sf1 promoter
of the ventromedial hypothalamic nucleus (VMH) resulted in
heightened susceptibility to diet-induced obesity, and conversely
mice overexpressing SIRT1 in these neurons are more resistant
to diet-induced obesity and insulin resistance (Ramadori et al.,
2011). It appears that SIRT1 activities in the hypothalamus are
generally associated with a metabolically favorable phenotype
that resembles that observed with CR/DR. On the other hand,
it has also been reported that SIRT1 neuron specific knockout
mice (with Cre recombinase controlled by of rat synapsin I
promoter) had increased insulin sensitivity and increased insulin
receptor signaling in peripheral tissues (Lu et al., 2013). Over-
expression of SIRT1 in the mouse forebrain was also shown to
result in obesity, impaired glucose tolerance and some defects
in motor function (Wu et al., 2011). These deviations attest to
the underlying complexities of the phenotypes resulting from
pharmacological and genetic manipulations, which is dependent
on the mice’s genetic background and the exact nature of
manipulation.
Another important aspect of SIRT1 activity which is tightly
connected to metabolic regulation that has recently come to
light is its role in the regulation of circadian rhythm (Maury
et al., 2010; Rey and Reddy, 2013). Central control of the
mammalian circadian rhythm resides in the hypothalamic
suprachiasmatic nucleus (SCN), and is regulated by a feedback
loop of transcription factor interactions. Brain and muscle Arnt-
like protein 1 (BMAL1) and CLOCK activate the expression of
PERIOD 1, 2 and 3 (PER1, 2, 3) and Cryptochrome 1 and
2 (Cry1, 2) genes, with the latter complexing at high levels
with the former, repressing their own transcription. The central
circadian timer protein CLOCK is a histone acetyltransferase,
and SIRT1 deacetylase activity appears to antagonize it in
a circadian manner (Nakahata et al., 2009). In peripheral
tissues, SIRT1 binds CLOCK-BMAL1 and is thus recruited
to the CLOCK-BMAL1 chromatin complex at circadian gene
promoters (Nakahata et al., 2008). It could deacetylate BMAL1
to affect its transcriptional activity (Nakahata et al., 2008),
and it could also deacetylate and promote the degradation
of PER2 (Asher et al., 2008). Clock-Bmal1 regulates the
circadian expression of nicotinamide phosphoribosyltransferase
(NAMPT), the rate-limiting enzyme in the NAD+ salvage
pathway (Nakahata et al., 2009; Ramsey et al., 2009), which is
in turn important for SIRT1 activity. While CLOCK promotes
NAMPT expression, inhibition of SIRT1, or of NAMPT by
FK866, promotes an early onset of circadian peak of circadian
genes like Per2 and Dbp (Nakahata et al., 2009). Thus, there
appears to be a feedback loop of CLOCK-BMAL1 transcriptional
regulation of clock genes involving NAMPT/NAD+ and SIRT1
(Figure 3).
An important notion that emerges and extended from the
above findings is that an essential aspect of SIRT1’s role in
aging and aging-associated metabolic diseases lies in its activity
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FIGURE 3 | SIRT1 roles in circadian rhythm regulation. In the
supraschiasmatic nucleus (SCN) at hypothalamus, CLOCK-BMAL1
activates the transcription of Cryptochrome (CRY) protein 1, 2 and
Period (PER) 1, 2, and 3 which in turn, directly repress CLOCK-BMAL1
activity. In addition, CLOCK-BMAL1 also regulates circadian expression
of NAMPT. Meanwhile, SIRT1 is recruited to the NAMPT promoter
and contributing to the synthesis of its own coenzyme, NAD+, which
is important for its deacetylation activity. SIRT1 also directly
contributes to circadian rhythms through deacetylation of BMAL1 and
PER2.
at the hypothalamus. As mentioned above, BRASTO mice
generated by Imai’s group had metabolic and aging parameters
that are superior to age-matched controls, and demonstrated
a delayed-aging phenotype and an increased lifespan (Satoh
et al., 2013). The phenotype of BRASTO mice was attributed
to an enhanced neural activity (as access by c-Fos expression)
and the expression of orexin type 2 receptor gene Ox2r at
the dorsomedial and lateral hypothalamic nuclei, and not
the arcuate and ventromedial hypothalamic nuclei in aged
BRASTO mice. Ox2r promoter activity was enhanced by SIRT1
expression through deacetylation of the transcription factor Nk2
homeobox1 (NKX2-1), and Sirt1-NKX2-1-Ox2r was proposed
by the authors to form a functional axis responsible for the
delayed-aging and increased lifespan phenotype. Interestingly, the
phenotypes could not be directly or causally related to SIRT1
expression in the arcuate nuclei, which influences food intake
and energy metabolism. Another BRASTO transgenic line with
SIRT1 expression that is much higher throughout the brain
and homogeneously higher throughout the hypothalamus does
not display delayed-aging or increased lifespan (Satoh et al.,
2013).
SIRT1’s regulation of the central control of circadian rhythm
is affected by aging. At the hypothalamic SCN, neuronal SIRT1
and PGC-1α bind cooperatively and in close proximity at the
Bmal1 promoter to regulate Bmal1 expression (Chang and
Guarente, 2013). In aged mice, decreased SIRT1 levels in the
SCN and reduced Bmal1 and Per2 perturbs the circadian rhythm
and impairs the ability to adapt to environmental light/dark
changes, a phenotype that is also exhibited by conditional SIRT1
knock-out in young mice. Overexpression of SIRT1 in the brain
counters the aging-associated circadian rhythm defects. As impair
circadian rhythm contributes critically to metabolic disorders,
this result suggests that SIRT1’s activity at the SCN is important
for delaying the onset of metabolic dysfunction that result from
impaired central control of circadian rhythm.
SIRT1’S ROLE IN CNS NEUROPROTECTION AND
NEURODEGENERATION
SIRT1 has been associated with a neuroprotective function in
a myriad of neuronal injury and neurodegeneration paradigms
(Gan and Mucke, 2008; Pallàs et al., 2008; Tang, 2009;
Donmez and Outeiro, 2013; Herskovits and Guarente, 2014).
A large number of studies using genetic and pharmacological
manipulation of SIRT1 activity in invertebrates and mice
models of neuronal injuries and disorders have been reported.
Interestingly, both activation and inhibition of SIRT1 have been
shown to be beneficial. It should also be noted that SIRT1
activities are not always pro-survival (Li et al., 2008; Ng and
Tang, 2013; Sansone et al., 2013). SIRT1 activation by resveratrol
(Raval et al., 2006) or transgenic overexpression of the protein
(Hernández-Jiménez et al., 2013) was shown to protect against
brain ischemic damages, as well as neuronal death in traumatic
brain injury (Zhao et al., 2012). On the other hand, the
SIRT1 inhibitor nicotinamide could also protect neurons against
excitotoxicity and cerebral ischemia (Liu et al., 2009). An early
study showed that resveratrol protected both C. elegans and
mouse neurons against the cytotoxicity of mutant huntingtin
(Parker et al., 2005). Later genetic manipulations in mice
appeared to confirm SIRT1’s beneficial effect in Huntington’s
disease (HD; Jeong et al., 2011; Jiang et al., 2011), but the
SIRT1 inhibitor selisistat was recently shown to alleviate HD
pathology in Drosophila and mouse models (Smith et al., 2014).
The beneficial effect of SIRT1 elevation or activation for models
of amyotrophic lateral sclerosis is more consistent (Kim et al.,
2007; Song et al., 2014). SIRT1 activity is also generally shown
to protect against toxic α-synuclein aggregates in worm and mice
models (van Ham et al., 2008; Donmez et al., 2012), and protected
dopaminergic neurons in the MPTP mouse model of Parkinson’s
disease (Mudò et al., 2012).
As far as aging and aging-associated disorder is concerned,
however, the main neurodegenerative disease of interest would be
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Alzheimer’s disease (AD; Ballard et al., 2011; Bonda et al., 2011)
and related dementias, which are discussed below.
Multiple evidences indicate that SIRT1 elevation or activation
is beneficial in AD and dementia (Braidy et al., 2012; Lalla
and Donmez, 2013). SIRT1’s attenuation of NF-κB signaling in
microglia was shown to be protective against neuronal death
induced by Aβ peptides (Chen et al., 2005). This role of SIRT1
in AD is apparently connected to CR/DR, which reduces Aβ
generation and amyloid plaque deposition in the brain of Tg2576
transgenic AD mice (Wang et al., 2005) and primate (Qin et al.,
2006a). SIRT1 activation by resveratrol was shown to protect
against toxicity induced by the cyclin-dependent kinase 5 (Cdk5)
activator p25, and mutant Cu/Zn superoxide dismutase 1 (SOD1)
in culture neurons and transgenic mice (Kim et al., 2007).
Furthermore, direct injection of SIRT1-expressing lentivirus into
the hippocampal CA1 region of p25 transgenic mice protected
against aging associated neurodegeneration (Kim et al., 2007).
In another AD mice model (bearing App(swe) and Psen1 dE9
transgenes), transgenic over-expression of SIRT1 in the brain
markedly reduced amyloid plaque formation, gliosis and decline
in learning and memory capabilities, while brain SIRT1 specific
knock-out had greatly attenuated lifespan likely due to juvenile
onset of an AD-like disease (Donmez et al., 2010). However,
contrasting the above, the SIRT1 inhibitor nicotinamide was
also shown to attenuate/delay cognitive effects of 3xTg-AD mice
(triple transgenic for mutant Psen1, App(swe) and Tau) via SIRT1
inhibition and reduction of Tau phosphorylation (Green et al.,
2008).
The mechanisms underlying the protective effect of SIRT1
and its activity in AD models are complex and multifaceted.
SIRT1’s reduction of Aβ generation appears unique to AD
pathology, and has thus been the focused of several studies
that yielded interesting and useful insights. Aβ production
requires the sequential action of β-secretase BACE1 and the
γ-secretase complex on the amyloid precursor protein (APP).
If APP is first cleaved by an α-secretase, a member of the A
Disintegrin and metalloproteinase (ADAM) family, its BACE1
recognition site is loss. Aβ production is effectively prevented
(Bandyopadhyay et al., 2007), and the product of α-secretase
cleavage, the soluble N-terminal fragment of APP (sAPPα), is
neuroprotective (Corrigan et al., 2012). SIRT1 over-expression
in primary neuron cultures from Tg2576 mouse reduced Aβ
secretion resulted in elevated levels of sAPPα and decreased
Rho-activated kinase 1 (ROCK1) expression. This mimicked the
phenotype elicited by caloric restriction (Qin et al., 2006b).
Incidentally, blood cholesterol-lowering inhibitors of 3-hydroxy-
3-methyl-glutaryl (HMG)-CoA reductase (statins) have also been
shown to improve cognitive function and amyloid phenotype
of AD models in multiple studies (Tong et al., 2009; Kurata
et al., 2011). Statins also increased sAPPα production (Pedrini
et al., 2005), which likely occurs via inhibition of ROCK
signaling, as statins also inhibit isoprenoid biosynthesis that
would affect the activity of Rho family GTPases upstream
of ROCK (Ma et al., 2009). A constitutively-active ROCK1,
which inhibited statin-stimulated sAPPα shedding, could in fact
attenuate the SIRT1-mediated response (Qin et al., 2006b). Recent
studies have indicated that the influence of Rho/ROCK signaling
FIGURE 4 | SIRT1’s roles in neuroprotection and neurodegeneration.
SIRT1 has a neuroprotective function through suppression of amyloid
β production. SIRT1 activates RARβ as a transcription factor of ADAM10,
which encodes α-secretase. The APP cleaved by α-secretase is no longer
able to generate Amyloid β peptides and this non-amyloidogenic cleavage is
therefore neuroprotective.
on amyloidogenesis is complex, involving the phosphorylation
of APP and modulation of BACE1 activity (Herskovits and
Guarente, 2014).
A more recent report has shown that SIRT1 could directly
activate the transcription of the α-secretase ADAM10, likely
via deacetylation of retinoic acid receptor β (RARβ), which
is known to activate ADAM10 transcription (Donmez et al.,
2010; Figure 4). SIRT1 over-expression in mouse neural N2a
cells expressing mutant APPswe have significantly elevated
ADAM10 and sAPPα levels, and cilostazol (an inhibitor of type
III phosphodiesterase) appears to suppress Aβ production in
a SIRT1-RAR-ADAM10-dependent manner (Lee et al., 2014).
SIRT1’s protective effect of AD-susceptible neurons may be
preceded by enhanced α-secretase-mediated non-amyloidogenic
APP processing, and a decline in SIRT1 levels in the aged
brain would therefore predispose its neurons to amyloidogenic
APP processing and AD. Not much yet is known about how
cholesterol and isoprenoid metabolism affects development and
progression of AD (Sun et al., 2014; Wood et al., 2014). However,
other connections between SIRT1, cholesterol metabolism and
AD exist. The apolipoprotein E e4 allele (ApoE4), a major
risk factor for AD (Hauser and Ryan, 2013), binds to APP
and significantly reduces sAPPα secretion, sAPPα/Aβ, and
sAPPα/sAPPβ ratios. In cell culture and AD postmortem tissue,
ApoE4 expression is shown to be associated with a decreased
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level of SIRT1 and increased level of SIRT2 (which is associated
with neurodegeneration Liu et al., 2012; Outeiro et al., 2007),
resulting in a decrease in SIRT1/SIRT2 ratio (Theendakara et al.,
2013). The decreased SIRT1/SIRT2 ratio is perhaps indicative of a
neuroprotective state that has been reversed by ApoE4 expression.
EPILOGUE
In the discussions above, we highlighted known and recently
revealed roles and activities of SIRT1 in the brain. Many previous
reports have attested to an improved metabolic status and health
at late stages of life with SIRT1 elevation and activation (reviewed
in Cantó and Auwerx, 2009a; Chaudhary and Pfluger, 2009;
Chang and Guarente, 2014), but evidence for actual lifespan
extension by SIRT1 is only recently reported (Satoh et al., 2013;
Mercken et al., 2014; Mitchell et al., 2014). We expounded on
the notion that SIRT1’s role at the late stages of life and lifespan
itself are linked with, and causally related to, its activities in the
brain. In particular, two key aspects of late stages of life that
are dependent on SIRT1 are normally loss, namely cognitive
function and metabolic regulation. The three strongest lines of
evidence in this regard are (1) SIRT1 is important for certain
aspects of neural connectivity and synaptic plasticity, (2) Loss
or decline in CNS SIRT1 activity occurs during aging, and this
deficit is directly associated with defined neurophysiological
and neuropathological mechanisms of cognitive decline and
metabolic dysfunction; and (3) SIRT1 overexpression in certain
neurons in the brain increased lifespan.
A more comprehensive understanding of SIRT1’s role
in CNS neurons, particularly those of the hypothalamus
and hippocampus, would hopefully aid future therapeutic
interventions. However, much remains to be learned.
Mouse experiments already calls for caution in analysis and
interpretation. A constitutive and global elevation of brain
SIRT1 (by whatever means) is unlikely to be helpful in an
all-encompassing manner in reversing cognitive and metabolic
dysfunctions. Notably, overexpression of brain SIRT1 in mice
has been reported to result in metabolic (Wu et al., 2011) and
cognitive (Kakefuda et al., 2009) defects. Our understanding
of SIRT1’s regulation of circadian rhythm is at an early stage,
and the roles of other nuclear sirtuins in this regard, such as
SIRT6, are being revealed (Masri and Sassone-Corsi, 2014).
SIRT6 also interacts with CLOCK-BMAL1, but probably not in
the same complex as SIRT1. Unlike SIRT1, it operates directly
at the transcription level by recruiting the clock machinery to
chromatin. An important role for SIRT6 is circadian chromatin
recruitment of SREBP-1, thus impinging on the circadian
regulation of a host of genes in fatty acid and cholesterol
metabolism (Masri et al., 2014). A thorough understanding of
how SIRT1 and SIRT6 differentially or synergistically regulate
the circadian mechanism would be of fundamental importance
(Masri and Sassone-Corsi, 2014).
An other important aspect of note is that beyond its role
in regulating gene expression via deacetylation of transcription
factors, Sirt1 is also a regulator of epigenetic changes. Sirt1
is a histone deacetylase (Hayakawa et al., 2015), and could
alter DNA methylation through its activity on factors such as
MeCP2 (Zocchi and Sassone-Corsi, 2012). A recent report in
mice showed that microglial SIRT1 deficiency influences both
aging-associated and tau-mediated memory deficits via the pro-
inflammatory cytokine IL-1β (Cho et al., 2015). Activation
of IL-1β transcription by SIRT1 deficiency appears to result
from IL-1β proximal promoter hypomethylation, a state that is
strongly associated with elevated IL-1β expression and aging.
A more defined understanding of the epigenetic impact of
SIRT1, either direct or indirect, on organismal aging via the
neurons would be highly desirable. On the other hand, molecules
linking SIRT1 to learning and memory are not yet fully
explored. The histone H2A variant, H2A.Z, a known mediator
of thermosensory response, was recently shown to play a role
in memory consolidation (Zovkic et al., 2014). Interestingly,
at least in some tissues, SIRT1 level and activity negatively
affect H2A.Z expression (Baptista et al., 2013). It is therefore
plausible that SIRT1’s role in learning and memory is connected
to its effect on H2A.Z expression, a notion that requires further
confirmation.
The mitochondrial SIRT3, SIRT4 and SIRT5 could also be
key regulators of metabolism (Hirschey et al., 2010; Laurent
et al., 2013a,b; Rardin et al., 2013; Weir et al., 2013), and the
interplay or crosstalk between nuclear SIRT1 and mitochondrial
SIRT3 in metabolic regulation and disorder is not yet understood
in detail. Sirtuin-mediated lifespan extension has now been
observed for SIRT1, SIRT6 (Kanfi et al., 2012), and under specific
circumstances, for SIRT2 (North et al., 2014). An understanding
of how mammalian sirtuins interact in complex traits like lifespan
would require much more work.
SIRT1’s neuroprotective function has also been extended by
recent findings, and it appears to play a role in the maintenance
of genomic stability in postmitotic neurons (Dobbin et al.,
2013). SIRT1 deacetylates and activates HDAC1 in the repair of
double stranded DNA breaks through the nonhomologous end-
joining pathway. In as far as learning and memory is concern,
SIRT1 and HDACs may have, albeit indirect, opposite functions.
While SIRT1 activation preserves memory and cognition (Gao
et al., 2010; Michán et al., 2010), HDAC inhibition enhances
cognition (Gräff and Tsai, 2013). HDAC inhibitors are known to
have varying effects on the levels of sirtuins, and trichostatin A
(TSA) and butyrate downregulate Sirt1 (Kyrylenko et al., 2003).
How sirtuins interact functionally with HDACs in their myriad
neuronal functions would also be an interesting and important
pursuit in the near future.
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